Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/15/16 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
67 | |
| 08/15/16 | Current report filing |
|
9 | ||
| 08/01/16 | Current report filing |
|
3 | ||
| 07/27/16 | Confidential treatment order |
|
1 | ||
| 06/30/16 | Notice of Effectiveness |
|
1 | ||
| 06/30/16 | Prospectus filed pursuant to Rule 424(b)(3) |
|
21 | ||
| 06/28/16 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 06/24/16 | SEC-generated letter |
|
2 | ||
| 06/22/16 | Current report filing |
|
35 | ||
| 06/14/16 | Registration statement for specified transactions by certain issuers |
|
34 |